These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 37422371)
1. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). Kates M; Chu X; Hahn N; Pietzak E; Smith A; Shevrin DH; Crispen P; Williams SB; Daneshmand S; Packiam VT; Porten S; Westerman ME; Wagner LI; Carducci M Eur Urol Focus; 2023 Jul; 9(4):561-563. PubMed ID: 37422371 [TBL] [Abstract][Full Text] [Related]
2. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer. Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180 [TBL] [Abstract][Full Text] [Related]
3. Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis. Bukavina L; Bell S; Packiam VT; Smaldone M; Abbosh P; Uzzo R; Kutikov A; Correa AF; Magee DE Urol Oncol; 2023 Sep; 41(9):391.e1-391.e4. PubMed ID: 37127478 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer. McElree IM; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT JAMA Netw Open; 2023 Feb; 6(2):e230849. PubMed ID: 36853609 [TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder. Patel SH; Gabrielson AT; Chan S; Schwartz D; Collins C; Singla N; Trock B; Bivalacqua TJ; Hahn N; Kates MR J Urol; 2024 Jul; 212(1):95-103. PubMed ID: 38653234 [TBL] [Abstract][Full Text] [Related]
6. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Tan WS; McElree IM; Davaro F; Steinberg RL; Bree K; Navai N; Dinney CP; O'Donnell MA; Li R; Kamat AM; Packiam VT Eur Urol Oncol; 2023 Oct; 6(5):531-534. PubMed ID: 37468392 [TBL] [Abstract][Full Text] [Related]
7. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now? Abou Chakra M; Packiam VT; Duquesne I; Peyromaure M; McElree IM; O'Donnell MA Expert Opin Pharmacother; 2024 Feb; 25(2):203-214. PubMed ID: 38264853 [TBL] [Abstract][Full Text] [Related]
8. Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial. Ansari Djafari A; Javanmard B; Razzaghi M; Hojjati SA; Razzaghi Z; Faraji S; Rahavian A; Garoosi M Urol J; 2023 Feb; 20(2):123-128. PubMed ID: 35689462 [TBL] [Abstract][Full Text] [Related]
13. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK. Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006 [TBL] [Abstract][Full Text] [Related]
14. Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534. Sung WW Eur Urol Oncol; 2024 Feb; 7(1):163. PubMed ID: 37679244 [No Abstract] [Full Text] [Related]
15. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Dinney CP; Greenberg RE; Steinberg GD Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238 [TBL] [Abstract][Full Text] [Related]
16. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro. Roumiguié M; Black PC Eur Urol Focus; 2022 Jul; 8(4):1117-1120. PubMed ID: 34593355 [TBL] [Abstract][Full Text] [Related]
17. Intravesical gemcitabine for non-muscle invasive bladder cancer. Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002 [TBL] [Abstract][Full Text] [Related]
18. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Yim K; Melnick K; Mott SL; Carvalho FLF; Zafar A; Clinton TN; Mossanen M; Steele GS; Hirsch M; Rizzo N; Wu CL; Mouw KW; Wszolek M; Salari K; Feldman A; Kibel AS; O'Donnell MA; Preston MA Urol Oncol; 2023 Nov; 41(11):458.e1-458.e7. PubMed ID: 37690933 [TBL] [Abstract][Full Text] [Related]
19. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101 [TBL] [Abstract][Full Text] [Related]
20. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]